SG&A Efficiency Analysis: Comparing Novartis AG and Biogen Inc.

SG&A Efficiency: A Tale of Two Giants

In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Novartis AG and Biogen Inc. have showcased contrasting trends in their SG&A expenditures.

Novartis AG: A Consistent Leader

From 2014 to 2023, Novartis AG consistently maintained higher SG&A expenses compared to Biogen Inc., peaking in 2018 with a 16% increase from 2014. Despite a dip in 2023, Novartis's strategic investments in administrative efficiency have kept them at the forefront.

Biogen Inc.: A Steady Climb

Biogen Inc., on the other hand, demonstrated a steady increase in SG&A expenses, with a notable 32% rise from 2014 to 2023. This growth reflects Biogen's expanding market presence and strategic focus on operational efficiency.

Conclusion

These trends highlight the diverse strategies employed by these pharmaceutical giants in managing their operational costs, offering valuable insights into their financial health and market strategies.